ライフサイエンスコーパス: foramen ovale

1 ntrast transcranial doppler to detect patent foramen ovale.

2 enosus, in both venae cavae, and through the foramen ovale.

3 y arteries and migraine patients with patent foramen ovale.

4 variations influence surgical access to the foramen ovale.

5 direct inferior vena caval flow towards the foramen ovale.

6 tcomes after transcatheter closure of patent foramen ovale.

7 ts who completed echocardiography had patent foramen ovale.

8 paradoxical embolism due to existing patent foramen ovale.

9 the stent was successfully positioned in the foramen ovale.

10 cell stent was positioned in an unrestricted foramen ovale.

11 dical therapy alone or closure of the patent foramen ovale.

12 ations or percutaneous closure of the patent foramen ovale.

13 sient ischemic attack (TIA) and had a patent foramen ovale.

14 ited to pulmonary artery stenosis and patent foramen ovale.

15 isolated atrial septal defect and/or patent foramen ovale.

16 , 0.95 to 1.21), atrial septal defect/patent foramen ovale (1.04, 0.88 to 1.24), neural tube defect (

17 Of 11 patients, 5 (45%) had a patent foramen ovale; 1 of these also had a primary lung carcin

18 (0, 160); umbilical vein, 134 (62, 206); and foramen ovale, 135 (37, 233).

19 16 (0, 34); umbilical vein, 29 (11, 47); and foramen ovale, 29 (7, 51).

20 .5% in patient with ECs; P<0.001) and patent foramen ovale (4.6% versus 13.5%; P=0.002).

21 (TAA), 88% had left-to-right flow across the foramen ovale, 91% had monophasic mitral inflow, and 94%

22 cted symptomatic patients, closure of patent foramen ovale after cryptogenic stroke, treatment of ins

23 Patent foramen ovale, alone or together with ASA, was not assoc

24 The prevalence of patent foramen ovale among patients with cryptogenic stroke is

25 The association of patent foramen ovale and atrial septal aneurysm with stroke is

26 Patients with a patent foramen ovale and ischemic stroke, transient ischemic at

27 elopment of anatomic variants such as patent foramen ovale and left atrial septal pouch.

28 Patent foramen ovale and pulmonary arteriovenous shunts are ass

29 aphy identified three patients with a patent foramen ovale and right-to-left shunt flow while breathi

30 d in 47% (including 17% with isolated patent foramen ovale), and 11% had undetermined stroke etiology

31 patients had simultaneous closure of patent foramen ovale, and 19 patients had other various cardiac

32 ne prevalence of atrial fibrillation, patent foramen ovale, and arterial stenoses were also similar f

33 (RAP) score (comprising the tricuspid valve, foramen ovale, and ductus venosus Doppler).

34 persistent pulmonary hypertension, a patent foramen ovale, and free-floating right-heart thrombus ar

35 ion of the inferior vena cava, right atrium, foramen ovale, and left atrium with a guidewire and 1.8F

36 sease, presence of left common trunk, patent foramen ovale, and time for atrial fibrillation diagnosi

37 ccult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atrial cardi

38 cryptogenic embolism in patients with patent foramen ovale are administration of antithrombotic medic

39 Structural heart disease and a patent foramen ovale are strongly associated with the presence

40 e closure (9 secundum ASDs and 4 with patent foramen ovale associated with a cerebral vascular accide

41 Foramen ovale blood flow (QFO = LVCO-QP) was estimated.

42 has been reported in patients with a patent foramen ovale, carcinoid tumor of the lung, and active c

43 natomic structures typically regress and the foramen ovale closes after birth.

44 results using these tools to perform patent foramen ovale closure are described.

45 in 4 and repair in 2, CABG in 2, and patent foramen ovale closure in 5.

46 Evidence from trials suggests that patent foramen ovale closure is superior to medical therapy alo

47 pparent increased risk for concurrent patent foramen ovale closure or mitral or tricuspid repair.

48 Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tac

49 patients who underwent transcatheter patent foramen ovale closure to prevent recurrent cerebrovascul

50 alysis demonstrated that simultaneous patent foramen ovale closure was not associated with an increas

51 n the impact of sex on outcomes after patent foramen ovale closure, however, remains scarce.

52 left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to

53 Occluder, are used for transcatheter patent foramen ovale closure.

54 k of developing device syndrome after patent foramen ovale closure.

55 th nickel hypersensitivity undergoing patent foramen ovale closure.

56 gulation for atrial fibrillation, and patent foramen ovale closure.

57 h cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offer a gre

58 a demonstration of both technologies, patent foramen ovale creation and closure was performed in a sw

59 mainly the adult population, such as patent foramen ovale device closure and closure of postinfarct

60 aware of these variations when accessing the foramen ovale during trigeminal neuralgia interventions.

61 f the ten patients undergoing semi-invasive (foramen ovale) electrode monitoring reveals that for at

62 ients, all of whom underwent recordings with foramen ovale electrodes and scalp electroencephalogram.

63 mesial temporal activity using intracranial foramen ovale electrodes in two patients with Alzheimer'

64 Closure of a patent foramen ovale for secondary prevention of cryptogenic em

65 One possible exception is patent foramen ovale, for which high-risk features may warrant

66 Patent foramen ovale has been associated with increased risk of

67 lowed by ostium secundum ASD in 6 and patent foramen ovale in 4.

68 benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic ischem

69 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS) evalua

70 th warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based

71 s (the PRIMA [Percutaneous Closure of Patent Foramen Ovale in Migraine With Aura] and PREMIUM [Prospe

72 hocardiograms in 11 patients showed a patent foramen ovale in one patient but no systemic source of e

73 that occur in the major veins and across the foramen ovale in the circulation of the fetal lamb.

74 en pulmonary embolism coexists with a patent foramen ovale, increased pressure in the right atrium ma

75 The foramen ovale is an essential component of the fetal cir

76 Whether closure of a patent foramen ovale is effective in the prevention of recurren

77 Patent foramen ovale is present in approximately 25% of all adu

78 e of percutaneous closure devices for patent foramen ovale is reviewed.

79 d paradoxical emboli in patients with patent foramen ovale is unknown.

80 Transcatheter closure of patent foramen ovale may prevent a substantial proportion of cr

81 rmal LV length, reversed flow in the TAA and foramen ovale, monophasic mitral inflow, and LV dysfunct

82 m-type atrial septal defect (n=12) or patent foramen ovale (n=5) by a totally endoscopic approach, ut

83 defect, secundum atrial septal defect/patent foramen ovale, neural tube defect, clubfoot, and oral cl

84 e (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23%), car

85 ing of intracranial atheroma, patent cardiac foramen ovale, or elevated levels of antiphospholipid an

86 re of secundum atrial septal defects, patent foramen ovale, patent ductus arteriosus, stent placement

87 ients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic ischemic s

88 A causal relationship between patent foramen ovale (PFO) and migraine has been hypothesized,

89 evention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained ischemic s

90 ischemic attack presumably related to patent foramen ovale (PFO) are at risk for recurrent cerebrovas

91 The role of a patent foramen ovale (PFO) as a risk factor for ischemic stroke

92 Patent foramen ovale (PFO) can be detected in up to 43% of pati

93 The main randomized trials evaluating patent foramen ovale (PFO) closure after a presumed PFO-associa

94 dence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complicatio

95 -documented, those for catheter-based patent foramen ovale (PFO) closure are still evolving.

96 patients who underwent transcatheter patent foramen ovale (PFO) closure for paradoxical embolism.

97 ical devices may be used "off-label." Patent foramen ovale (PFO) closure is indicated to reduce recur

98 Percutaneous transcatheter patent foramen ovale (PFO) closure is now standard practice and

99 Patent foramen ovale (PFO) closure is the gold standard for tre

100 Transcatheter patent foramen ovale (PFO) closure is the recommended treatment

101 ional studies have shown percutaneous patent foramen ovale (PFO) closure to be a safe means of reduci

102 Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke

103 served in up to 25% of patients after patent foramen ovale (PFO) closure, but its long-term influence

104 eft atrial appendage (LAA) occlusion, patent foramen ovale (PFO) closure, transcatheter aortic valve

105 Patent foramen ovale (PFO) describes a valve in the interatrial

106 The role of surgical closure of patent foramen ovale (PFO) for cerebral infarction (CI) or tran

107 close atrial septal defects (ASD) and patent foramen ovale (PFO) has a number of limitations, includi

108 Patent foramen ovale (PFO) has been associated with migraine, b

109 Adults with a patent foramen ovale (PFO) have a greater tendency to develop s

110 ss the risk of ischemic stroke from a patent foramen ovale (PFO) in the multiethnic prospective cohor

111 The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent strok

112 The patent foramen ovale (PFO) is a normal interatrial communicatio

113 Patent foramen ovale (PFO) is associated with cryptogenic strok

114 Patent foramen ovale (PFO) is associated with stroke, but there

115 Patent foramen ovale (PFO) is experiencing increased clinical i

116 Patent foramen ovale (PFO) is implicated in platypnea-orthodeox

117 Patent foramen ovale (PFO) is implicated in the pathogenesis of

118 astomoses (IPAVA) in humans without a patent foramen ovale (PFO) is negatively correlated with pulmon

119 Patent foramen ovale (PFO) is prevalent in patients with migrai

120 Percutaneous transcatheter closure of patent foramen ovale (PFO) is used as an alternative to surgery

121 A patent foramen ovale (PFO) may permit arterial embolization of

122 ectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus medical

123 Patent foramen ovale (PFO) prevalence was 47% in Tibetans and H

124 zed that paradoxical embolism through patent foramen ovale (PFO) should be the main mechanism.

125 factors, regular dentist visits, and patent foramen ovale (PFO) status.

126 Patent foramen ovale (PFO) was detected with contrast injection

127 -to-left shunted blood flow through a patent foramen ovale (PFO) would not be cooled.

128 A patent foramen ovale (PFO), an opening between the right and le

129 with atrial septal aneurysm (SA) and patent foramen ovale (PFO), and to determine the efficacy of me

130 to determine the association between patent foramen ovale (PFO), atrial septal aneurysm (ASA), and s

131 headache symptoms in patients with a patent foramen ovale (PFO), both of which conditions are highly

132 milder form of atrial septal defect, patent foramen ovale (PFO), exists in about one-quarter of the

133 to evaluate the relationship between patent foramen ovale (PFO), ischemic stroke, and subclinical ce

134 Controversy surrounds the issue of patent foramen ovale (PFO), stroke, and secondary prevention st

135 nt ischemic stroke, and prevalence of patent foramen ovale (PFO).

136 res to repair incidentally discovered patent foramen ovale (PFO).

137 ulting in a right-to-left shunt via a patent foramen ovale (PFO).

138 including ischaemic stroke [through a patent foramen ovale (PFO)].

139 utility in quantitative assessment of patent foramen ovales (PFO).

140 Patent foramen ovales (PFOs) are common congenital cardiac defe

141 Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic

142 patients with cryptogenic stroke and patent foramen ovale-related ischemic stroke to receive either

143 diseases causing stroke, the role of patent foramen ovale remains controversial.

144 A strong inverse relationship between foramen ovale shunt and pulmonary blood flow was noted (

145 The wide range we found in foramen ovale shunting suggests a degree of variability

146 compression sickness with concomitant patent foramen ovale that was successfully closed contrary to s

147 closure of an atrial septal defect or patent foramen ovale to assess how the procedure affected migra

148 sus stream preferentially passed through the foramen ovale to the left atrium.

149 ifty-four (86%) had effective closure of the foramen ovale (trivial or no residual shunt by echocardi

150 Patent foramen ovales vary in both anatomical and functional si

151 Foramen ovale volume blood flow (left ventricular cardia

152 <.001), and DA volume blood flow (P<.01) and foramen ovale volume blood flow (P<.03) decreased.

153 cept for 19.6 +/- 2.3% of the cycle when the foramen ovale was closed during atrial contraction.

154 In the second group, the patent foramen ovale was not successfully created in 1 animal,

155 of medical therapy (895 patients) for patent foramen ovale were included.

156 theter closure or medical therapy for patent foramen ovale were required to include at least 10 patie

157 All patent foramen ovales were completely closed in the first group

158 Here, we report stenting of the foramen ovale with a large, open-cell stent via percutan

159 ly assigned to undergo closure of the patent foramen ovale with the Amplatzer PFO Occluder or to rece